You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股CXO板塊集體下挫,美《生物安全法案》或納入更多中國CXO公司
港股CXO板塊集體下挫,截至半日收盤,昭衍新藥跌近10%,康龍化成跌超7%,泰格醫藥跌超6%,藥明康德、凱萊英跌超5%,金斯瑞和藥明生物跌超4%。據Endpoints,最近幾周,涉及藥明康德的美國生物安全法案使得美國製藥商重新考慮與藥明康德之間的關係。整個美國生物製藥行業也開始考慮限制更多中國CXO公司的可能性。據悉,美國生物安全法案(The Biosecure Act)可能納入除藥明康德之外更多的中國CXO公司,包括總部位於北京的康龍化成及總部位於南京的提供基因合成服務的金斯瑞等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.